about
MIA is a potential biomarker for tumour load in neurofibromatosis type 1Lasofoxifene in postmenopausal women with osteoporosisStrontium ranelate--data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action.Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.The 2002 Canadian bone densitometry recommendations: take-home messages.A review of strontium ranelate and its effect on DXA scans.Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.Diagnosis and management of vertebral fractures in elderly adults.Management of osteoporosis in men: an update and case exampleStandards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children.Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.Preventing fractures in postmenopausal women: how to assess risk.Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference.Standards for performing DXA in individuals with secondary causes of osteoporosis.The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future.Bone strength: the whole is greater than the sum of its parts.High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group.Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry.Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.Bisphosphonate associated osteonecrosis of the jaw.Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.International Society for Clinical Densitometry official positions: Asia-Pacific Region consensus.Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium.The Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition.Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.Osteoporosis: therapies now and in the future.Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.Dual-Energy X-Ray Absorptiometry Technical issues: the 2007 ISCD Official Positions.Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
P50
Q21245252-76CBD6B8-297C-446B-B7B1-6742D930A89DQ28274186-59BD7479-18B9-489E-9B33-BEAFF0D750D5Q31033939-72924251-C52D-4343-B4AD-C009DCDEA2F1Q34263882-E2092A4E-4903-4C74-ADE2-C219E9A087C6Q34292278-4C739EAC-D3BA-4D24-A7F0-723004DE0F9DQ34579278-E9D5D02A-8BD2-4A79-8FD0-5F086FECDD7AQ34656025-1632CE81-9C27-47B1-A61E-0E6C4C0D4211Q34809271-F9EB9897-91CB-4DDF-A867-92A408BF79AFQ35607079-3FDC8E7B-0E25-4F7A-BB26-BE4F72D5AC4EQ35638164-820859DA-9069-486A-9AE3-0CAF404B8221Q35644204-F039B458-B7F4-419D-BD87-19ED8D3F970EQ35663997-362A4A5C-ADD2-45BD-BA5D-02A84158D153Q35680543-A3C37B80-164E-48B7-9B58-650A81B51B87Q36071882-1025C74D-C372-4233-A906-06078A0988E7Q36153174-40DB729D-4DD2-4746-85E8-BF5E9BE09EE9Q36164799-94CBF818-5278-493B-BAF6-931152F6743CQ36491290-269164F3-E48B-4406-8798-CB50A51E4A2FQ36491311-1BC2D27F-9E1B-41AC-98BA-FD9DF4B89ED3Q36556162-2B866A59-7BF0-4404-920B-A828908D9365Q36556165-6D413BD5-B6F4-485C-AA3C-4E2B9AEDDCB3Q36809342-F12197D3-254F-41FA-BF90-60D851C0996EQ36813514-734D0EA7-9022-4AC2-8B97-54EC60F7003AQ37149616-4B9D5CAD-17CA-447C-9482-F6B64D95B265Q37182980-1559E3DB-8D64-45E9-B0D5-0C2C8C8C6F72Q37404701-5AE3FBE9-91CF-4A65-8C18-C8BA879CBB10Q37415072-798A1D01-B680-4B61-90F8-C3CCF53813ABQ37620991-39FD951F-A4D7-4DF2-A790-E9002FAA81F3Q37776059-C61F3416-921A-4519-8EF2-CAE96F22B9D9Q37910421-E46F8E7C-5BC4-4D75-A202-3559140FC524Q38062171-281A7E27-67AF-46F1-BE3A-F432B28CBA88Q38088574-05DE680D-2391-4507-AF5F-99C60A433CBFQ38148826-901F8AB2-F850-4ECB-9254-483905B0627AQ38400926-378F3628-0711-4428-AACE-396E0C4CCECCQ39695112-408D96DF-A1E9-4BDA-B59E-1154ACC46A4EQ43038398-F044B791-5BB7-426D-8FFF-F4CF935BBE20Q43055100-A4C54BAD-7A46-46E8-834E-F826FD30DCB1Q43628983-45C4F5D1-A164-4CF8-BE7B-45BB6F21874BQ44921653-DBD6E80F-8E53-4E34-BEBA-66E9343ED2C1Q44945120-1CCD9E70-015C-4E8B-8D07-8A4F46267975Q45931469-3C5AEC78-CF4D-41FF-8175-DDB212531F9F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Kendler
@ast
David Kendler
@en
David Kendler
@es
David Kendler
@nl
David Kendler
@sl
type
label
David Kendler
@ast
David Kendler
@en
David Kendler
@es
David Kendler
@nl
David Kendler
@sl
prefLabel
David Kendler
@ast
David Kendler
@en
David Kendler
@es
David Kendler
@nl
David Kendler
@sl
P106
P21
P31
P496
0000-0001-7679-3965